Free Trial

Alumis (NASDAQ:ALMS) Sets New 1-Year Low Following Analyst Downgrade

Alumis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alumis shares hit a new 52-week low, trading as low as $5.22 after Oppenheimer cut its price target to $28, though it maintained an outperform rating.
  • Analyst opinions remain broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average target of $31.27, despite recent target cuts from several firms.
  • Director Srinivas Akkaraju bought 546,581 shares for about $5.8 million in September. Alumis also slightly beat quarterly earnings and revenue expectations, reporting a loss of $0.73 per share on $1.91 million in revenue.
  • Five stocks we like better than Alumis.

Alumis Inc. (NASDAQ:ALMS - Get Free Report)'s share price reached a new 52-week low during trading on Monday after Oppenheimer lowered their price target on the stock to $28.00. Oppenheimer currently has an outperform rating on the stock. Alumis traded as low as $5.22 and last traded at $5.1960, with a volume of 319,044 shares traded. The stock had previously closed at $5.60.

A number of other brokerages have also recently weighed in on ALMS. Morgan Stanley dropped their target price on shares of Alumis from $39.00 to $29.00 and set an "overweight" rating on the stock in a report on Wednesday, September 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a report on Wednesday, September 16th. Weiss Ratings raised shares of Alumis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday. HC Wainwright lowered their price objective on shares of Alumis from $15.00 to $9.00 and set a "buy" rating for the company in a research report on Friday. Finally, Benchmark reiterated a "buy" rating on shares of Alumis in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alumis presently has an average rating of "Moderate Buy" and a consensus target price of $31.27.

Get Our Latest Research Report on Alumis

Insider Buying and Selling

In related news, Director Srinivas Akkaraju acquired 546,581 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was purchased at an average cost of $10.63 per share, for a total transaction of $5,810,156.03. Following the purchase, the director directly owned 4,937,026 shares in the company, valued at $52,480,586.38. This represents a 12.45% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 99,754 shares of company stock worth $1,037,804. 33.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alumis

Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP increased its holdings in shares of Alumis by 188.7% in the 3rd quarter. Marshall Wace LLP now owns 1,062,571 shares of the company's stock worth $7,852,000 after acquiring an additional 694,557 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Alumis during the 3rd quarter valued at about $706,000. Polymer Capital Management US LLC acquired a new position in Alumis during the 3rd quarter valued at about $152,000. First Trust Advisors LP grew its position in Alumis by 244.8% in the 3rd quarter. First Trust Advisors LP now owns 324,311 shares of the company's stock worth $2,397,000 after purchasing an additional 230,265 shares during the last quarter. Finally, Ieq Capital LLC bought a new position in Alumis in the 3rd quarter worth about $306,000.

Alumis Trading Down 8.7%

The firm's 50-day simple moving average is $7.24 and its 200 day simple moving average is $20.46. The stock has a market cap of $662.06 million, a P/E ratio of -1.47 and a beta of -0.28.

Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.03. The company had revenue of $1.91 million for the quarter, compared to analysts' expectations of $1.90 million. Alumis had a negative return on equity of 89.77% and a negative net margin of 5,844.54%. On average, analysts anticipate that Alumis Inc. will post -2.95 EPS for the current year.

Alumis Company Profile

(Get Free Report)

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alumis Right Now?

Before you consider Alumis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.

While Alumis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines